3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
4
Seroma
3
Pancreatic Neoplasms
2
Rectal Diseases
1
Prostatic Neoplasms
1
Patient Satisfaction
1
Pancreatitis
1
Pain, Postoperative
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms by Site
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Interventions
Irinotecan
4
Bevacizumab
3
Oxaliplatin
2
Leucovorin
2
Fluorouracil
2
Cyclophosphamide
2
Cetuximab
2
Capecitabine
2
pembrolizumab
1
napabucasin
1
guadecitabine
1
encorafenib
1
Sutures
1
Surgical Instruments
1
Pemetrexed
1
Oviposition
1
Ocoxin
1
Levoleucovorin
1
Leukocyte Immunoglobulin-like Receptor B1
1
KRN-330
1
Drug Therapy
1
Drainage
1
Chemoradiotherapy
1
Aspirin
1
Ascorbic Acid
1
5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide
1
5,10-methylenetetrahydrofolic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Rectal Diseases
×
Drainage
×
Clear all
NCT01269567
2026-05-14
GRECCAR 5
University Hospital, Bordeaux
Phase 3
Completed
494 enrolled